Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications

Journal of Medicinal Chemistry

Volumn 48, Issue 9, 2005, Pages 3141-3152

  Van Zandt, Michael C ^a   Jones, Michael L ^a   Gunn, David E ^a   Geraci, Leo S ^a   Jones, J Howard ^a   Sawicki, Diane R ^a   Sredy, Janet ^a   Jacot, Jorge L ^a   DiCioccio, A Thomas ^a   Petrova, Tatiana ^b   Mitschler, Andre ^b   Podjarny, Alberto D ^b  

^a The Institute for Diabetes Discovery   (United States)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(3 BROMO 2 BENZO[B]FURANYL)SULFONYL]HYDANTOIN; 2 (4 BROMO 2 FLUOROBENZYL)SPIRO[1,2,3,4 TETRAHYDROPYRROLO[1,2 A]PYRAZINE 4,3' PYRROLIDINE] 1,2',3',5' TETRAONE; 3 [(4,5,7 TRIFLUOROBENZOTHIAZOL 2 YL)METHYL] 5 METHYLPHENYLACETIC ACID; 3,4 DIHYDRO 2,8 DIISOPROPYL 3 THIOXO 2H 1,4 BENZOXAZINE 4 ACETIC ACID; ALDEHYDE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; BENZOTHIAZOLE DERIVATIVE; EPALRESTAT; FIDARESTAT; IMIRESTAT; LIDORESTAT; MINALRESTAT; POLYOL; PONALRESTAT; RISARESTAT; SG 210; SORBINIL; SORBITOL; STREPTOZOCIN; TOLRESTAT; UNCLASSIFIED DRUG; WP 921; ZENARESTAT; ZOPOLRESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DIABETES MELLITUS; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; IC 50; LENS; MALE; MOTOR NERVE CONDUCTION; NERVE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT;

ALDEHYDE REDUCTASE; ANIMALS; CATARACT; CHRONIC DISEASE; CRYSTALLOGRAPHY, X-RAY; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; HUMANS; INDOLEACETIC ACIDS; LENS, CRYSTALLINE; MALE; MODELS, MOLECULAR; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TISSUE DISTRIBUTION;

EID: 20944432343     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0492094     Document Type: Article

References (66)

1. American Diabetes Association's homepage. http://www.diabetes.org.
2. (a) The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329, 977-986.
3. (b) The United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonyl-ureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998, 352, 837-853.
4. (a) Textbook of Diabetes; Pickup, J. C., Williams, G., Eds.; Blackwell Science Ltd: United Kingdom, 1997; Vol. 1, Chapter 42.
5. (b) Williamson, J. R.; et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993, 42, 801-813.
6. (c) Setter, S. M.; Campbell, R. K.; Cahoon, C. J. Biochemical pathways for microvascular complications of diabetes mellitus. Ann. Pharmacother. 2003, 37, 1858-1866.
7. Mylari, B. L.; Armento, S. J.; Beebe, D. A.; Conn, E. L.; Coutcher, J. B.; Dina, M. S.; O'Gorman, M. T.; Linhares, M. C.; Martin, W. H.; Oates, P. J.; Tess, D. A.; Withbroe, G. J.; Zembrowski, W. J. A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl) -2-H-pyridazin-3-one. J. Med. Chem. 2003, 46, 2283-2286.
8. Greene, D. A.; Sima, A. F. A.; Stevens, M. J.; Feldman, E. L.; Lattimer, S. A.; Complications: Neuropathy, pathogenetic considerations. Diabetes Care 1992, 15, 1902-1925.
9. Green, D. A.; Lattimer, S. A.; Sima, A. A. F. Sorbitol, pophoinosititides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications, N. Engl. J. Med. 1987, 316, 599-606.
10. Lee, A.; Chung, S. K.; Chung, S. S. Demonstration that polyol accumulation is responsible for diabetic cataract by use of transgenic mice expressing the aldose reductase gene in the lens. Proc. Natl. Acad. Sci. 1995, 92, 2780-2784.
11. (a) Oates, P. J.; Mylari, B. L. Aldose reductase inhibitors: Therapeutic implications for diabetic complications. Exp. Opin. Invest. Drugs 1999, 8, 1-15.
12. (b) Ramasamy, R. Aldose reductase: A novel target for cardioprotective interventions. Current Drug Targets 2003, 4, 625-632.
13. (a) Kao, Y.-L.; Donahue, K.; Chan, A.; Knight, J.; Silink, M. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with Type I diabetes. Diabetes 1999, 48, 1338-1340.
14. (b) Heesom, A.; Hibberd, M.; Millward, A.; Demaine, A. Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes 1997, 46, 287-291.
15. (c) Moczulski, D.; et al. The role of aldose reductase gene in the susceptibility to diabetic nephropathy in type II (non-insulin-dependent) diabetes mellitus. Diabetologia 1999, 42, 94-97.
16. (d) Demaine, A.; Cross, D.; Millward, A. Polymorphism of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest. Ophthalmol. Visual Sci. 2000, 41, 4064-4068.
17. (e) Heesom, A. E.; Millward, A.; Demaine, A. G. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′-end of the aldose reductase gene. J. Neurol., Neurosurg. Psychiat. 1998, 64, 213-216.
18. (f) Taverna, M. J. Genetics of diabetic complications: Retinopathy. Ann. Endocrinol. 2004, 65 (Suppl. 1), 1S17-1S25.
19. Ho, E. C. M.; Lam, K. S. L.; Chung, S. S. M. Aldose reductase deficient mice are alleviated from depletion of GSH in the peripheral nerve and MNCV deficit associated with diabetes. Diabetes 2001, 50, 59.
20. (a) Lajer, M.; Tarnow, L.; Fleckner, J.; Hansen, B. V.; Edwards, D. G.; Parving, H.; Boel, E. Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in caucasian type 1 diabetic patients. Diabetic medicine 2004, 21, 867-873.
21. (b) Sivenius, K.; Pihlajamaki, J.; Partanen, J.; Niskanen, L.; Laakso, M.; Uusitupa, M. Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. Diabetes Care 2004, 27, 2021-2026.
22. (a) Miyamoto, S. Recent advances in aldose reductase inhibitors: Potential agents for the treatment of diabetic complications. Exp. Opin. Ther. Patents 2002, 12, 621-631.
23. (b) Suzen, A.; Buyukbingol, E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr. Med. Chem. 2003, 10, 1329-1352.
24. Hamada, Y.; Nakamura, J. Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treatments Endocrinol. 2004, 3, 245-255.
25. (a) Shinoda, M.; Mori, S.; Shintani, S.; Ishikura, S.; Hara, A. Inhibition of Human Aldehyde Reductase by Drugs for Testing the Function of Liver and Kidney. Biol. Pharm. Bull. 1999, 22, 741-744.
26. (b) Suzuki, K.; Koh, Y. H.; Mizuno, H.; Hamaoka, R.; Taniguchi, N. Overexpression of aldehyde reductase protects PC12 cells from the cytotoxicity of methylglyoxal or 3-deoxyglucosone. J. Biochem. 1998, 123, 353-357.
27. (a) Takahashi, M.; Fujii, J.; Teshima, T.; Suzuki, K.; Shiba, T.; Taniguchi, N. Identity of a major 3-deoxyglucosone-reducing enzyme with aldehyde reductase in rat liver established by amino acid sequencing and cDNA expression. Gene, 1993, 127, 249-253.
28. (b) Kanazu, T.; Shinoda, M.; Nakayama, T.; Deyashiki, Y.; Hara, A.; Sawada, H. Aldehyde reductase is a major protein associated with 3-deoxyglucosone reductase activity in rat, pig and human livers. Biochem. J. 1991, 279, 903-906.
29. Hamada, Y.; Araki, N.; Koh, N.; Nakamura, J.; Horiuchi, S.; Hotta, N. Rapid formation of advanced glycation end-products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem. Biophys. Res. Commun. 1996, 228, 539-543.
30. (a) Oya, T.; Hattori, N.; Mizuno, Y.; Miyata, S.; Maeda, S.; Osawa, T.; Uchida, K. Methylglyoxal Modification of Protein. J. Biol. Chem. 1999, 274, 18492-18502.
31. (b) Cavalot, F.; Anfossi, G.; Russo, I.; Mularoni, E.; Massucco, P.; Mattiello, L.; Burzacca, S.; Hahn, A.; Trovati, M. Nonenzymatic Glycation of Fibronectin Impairs Adhesive and Proliferative Properties of Human Vascular Smooth Muscle Cells. Metabolism 1996, 45, 285-292.
32. (c) Fu, M.; Wells-Knecht, K.; Blackledge, J. Lyons, T.; Thorpe, S.; Baynes, J. Glycation, Glycoidation, and cross-Linking of Collagen by Glucose. Diabetes 1994, 43, 676-683.
33. (a) Aotsuka, T.; Abe, N.; Fukushima, K.; Ashizawa, N.; Yoshida, M. Benzothiazol-2-yl carboxylic acids with diverse spacers: A novel class of potent, orally active aldose reductase inhibitors. Bioorg. Med. Chem Lett., 1997, 7, 1677-1682.
34. (b) Aotsuka, T.; Hosono, H.; Kurihara, T.; Nakamura, Y.; Matsui, T.; Kobayashi, F. Chem. Pharm. Bull. 1994, 42, 1264-1271.
35. (c) Matsui, T.; Nakamura, Y.; Ishikawa, H.; Matsuura, A.; Kobayashi, F. Jpn. J. Pharmacol. 1994, 64, 115.
36. Somei, M.; Kizu, K.; Kunimoto, M.; Yamada, F. Chem. Pharm. Bull. 1985, 33, 3996.
37. Urzhumtsev, A.; Tête-Favier, F.; Mitschler, A.; Barbanton, J.; Barth, P.; Urzhumtseva, L.; Biellmann, J.-F.; Podjarny, A. D.; Moras, D. A. 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 1997, 5, 601-612.
38. (a) El-Kabbani, O.; Wilson, D. K.; Petrash, J. M.; Quiocho, F. A. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. Mol. Vis. 1998, 4, 19-25.
39. (b) Rees-Milton, K. J.; Jia, Z.; Green, N. C.; Bhatia, M.; El-Kabbani, O.; Flynn, T. G. Aldehyde reductase: The role of C-terminal residues in defining substrate and cofactor specificities. Arch. Biochem. Biophys. 1998, 355, 137-144.
40. (c) El-Kabbani, O.; Carper, D. A.; McGowan, M. H.; Devedjiev, Y.; Rees-Milton, K. J.; Flynn, T. G. Studies on the inhibitor-binding site of porcine aldehyde reductase: Crystal structure of the holoenzyme-inhibitor ternary complex. Proteins 1997, 29, 186-192.
41. (d) Sotriffer, C. A.; Kramer, O.; Klebe, G. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations. Proteins: Struct., Funct. Bioinformatics 2004, 56, 52-66.
42. (e) Harrison, D. H. T.; Bohren, K. M.; Petsko, G. A.; Ringe, D.; Gabbay, K. H. The alrestatin double-decker: Binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant. Biochemistry 1997, 36, 16134-16140.
43. (a) El-Kabbani, O.; Ruiz, F.; Darmanin, C.; Chung, R. P. Aldose reductase structures: Implications for mechanism and inhibition. Cell. Mol. Life Sci. 2004, 61, 750-762.
44. (b) Petrash, J. M. All in the family: Aldose reductase and closely related aldo-keto reductases. Cell. Mol. Life Sci. 2004, 61, 737-749.
45. Mylari, B.; Larson, E.; Beyer, T.; Zembrowski, W.; Aldinger, C.; Dee, M.; Siegel, T.; Singleton, D. Novel, potent aldose reductase inhibitors: 3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazoyl]methyl] -1-phthalazine-acetic acid (zopolrestat) and congeners. J. Med. Chem. 1991, 34, 108-122.
46. (a) Nagata, M.; Hohman, T. C.; Nishimura, C.; Drea, C. M.; Oliver, C.; Robison, W. G., Jr. Polyol and vacuole formation in cultured canine lens epithelial cells. Exp. Eye Res. 1989, 48, 667-677.
47. (b) Kinoshita, J. H. Aldose reductase in the diabetic eye. XLIII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 1986, 102, 685-692.
48. (c) Cogan, D. G.; Kinoshita, J. H.; Kador, P. F.; Robison, W. G., Jr.; Datilis, M. B.; Cobo, L. M.; Kupfer, C. Aldose reductase and complications of diabetes. Ann. Intern. Med. 1984, 101, 82-91.
49. Lerner, B. C.; Varma, S.; Richards, R. Polyol pathway metabolites in human cataracts. Arch. Ophthalmol. 1984, 102, 917-920.
50. Values for drug-treated diabetic patients in study and typical untreated diabetic patients (not in current study) provided by Dr. Henry Powell, M.D., D.Sc., University of California, San Diego.
51. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2475-2483.
52. Hayman, S.; Kinoshita, J. H. J. Biol. Chem. 1965, 240, 877-880.
53. Barski, O. A.; Gabbay, K. H.; Grimshaw, C. E.; Bohren, K. M. Mechanism of human aldehyde reductase: Characterization of the active site pocket. Biochemistry 1995, 34, 11264-11275.
54. (a) Stribling, D.; Mirrlees, D. J.; Harrison, H. E.; Earl, D. C. N. Properties of ICI 128,436 a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat. Metabolism 1985, 4, 336-344.
55. (b) Ashizawa, N.; Yoshida, M.; Sugiyama, Y.; Akaike, N.; Ohbayashi, S.; Aotsuka, T.; Abe, N.; Fukushima, K.; Matsuura, A. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Jpn. J. Pharmacol. 1997, 73, 133-144.
56. +/NADPH and alrestatin-like inhibitors. Biochemistry 1994, 33, 7157-7165.
57. Barski, O. A.; Gabbay, K. H.; Grimshaw, C. E.; Bohren, K. M. Mechanism of human aldehyde reductase: Characterization of the active site pocket. Biochemistry 1995, 34, 11264-11275.
58. (a) Bergmeyer, H. U.; Gruber, W.; Gutmann, I. Methods of Enzymatic Analysis 2nd ed.; Bergmeyer, H. U., Ed.; Weinheim and Academic Press: New York, 1974; Vol. 3, pp 1323-1330.
59. (b) Malone, J. I.; Knox, G.; Benford, S.; Tedesco, T. A. Red cell sorbitol. An indicator of diabetic control. Diabetes 1980, 29, 861-864.
60. Sharma, A. K.; Thomas, P. K. Peripheral nerve structure and function in experimental diabetes. J. Neurol. Sci. 1974, 23, 1-15.
61. Schnatz, J. D.; Furmaniak, J. M.; Chlouverakis, C. The origin of hypertriglyceridema in streptozotocin diabetic rats. Diabetologia 1972, 8, 125-130.
62. Trinder, P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969, 6, 24.
63. Otwinowski, Z.; Minor, W. Methods in Enzymology, Macromolecular Crystallography; Carter, C. W., Jr., Sweet, R. M., Eds.; Academic Press: New York, 1997; Vol. 276, Part A, pp 307-326
64. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. O. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. 1991, A47, 110-119.
65. Brunger, A. T. X-PLOR, version 3.1. A system for X-ray crystallography and NMR. Yale University Press: New Haven, CT, 1992.
66. Sheldrick, G. M.; Schneider, T. R. Shelxl-high-resolution refinement. Methods Enzymol. 1997, 277, 319-343.